Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting
在真实世界临床环境中，对亚洲晚期肾细胞癌患者使用纳武利尤单抗治疗3 mg/kg剂量和240 mg固定剂量时的暴露量和临床安全性进行分析
期刊:Translational Oncology
影响因子:4.1
doi:10.1016/j.tranon.2020.100771
Kato, Renpei; Ikarashi, Daiki; Matsuura, Tomohiko; Maekawa, Shigekatsu; Kato, Yoichiro; Kanehira, Mitsugu; Takata, Ryo; Tokuyama, Rie; Tamai, Kanako; Harigai, Naoto; Nakazaki, Yukoh; Obara, Wataru
